- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.37 Å
- Oligo State
- hetero-4-4-mer
- Ligands
- 4 x MTA: 5'-DEOXY-5'-METHYLTHIOADENOSINE(Non-covalent)
- 4 x 01: N-(4-amino-1H-pyrazolo[4,3-c]pyridin-7-yl)-2-[(2R,5S)-2-(1,3-benzothiazol-5-yl)-5-methylpiperidin-1-yl]-2-oxoacetamide
01.2: 15 residues within 4Å:- Chain A: Q.317, S.318, L.320, V.334, F.335, K.341, E.443, L.445, E.452, V.511, F.585, S.586, W.587, F.588
- Ligands: MTA.1
17 PLIP interactions:17 interactions with chain A- Hydrophobic interactions: A:Q.317, A:L.320, A:L.320, A:V.334, A:F.588
- Hydrogen bonds: A:Q.317, A:K.341, A:L.445, A:E.452, A:S.586, A:S.586, A:F.588
- pi-Stacking: A:F.335, A:F.335, A:W.587, A:W.587, A:W.587
01.17: 15 residues within 4Å:- Chain C: Q.317, S.318, L.320, V.334, F.335, K.341, E.443, L.445, E.452, V.511, F.585, S.586, W.587, F.588
- Ligands: MTA.16
17 PLIP interactions:17 interactions with chain C- Hydrophobic interactions: C:Q.317, C:L.320, C:L.320, C:V.334, C:F.588
- Hydrogen bonds: C:Q.317, C:K.341, C:L.445, C:E.452, C:S.586, C:S.586, C:F.588
- pi-Stacking: C:F.335, C:F.335, C:W.587, C:W.587, C:W.587
01.32: 15 residues within 4Å:- Chain E: Q.317, S.318, L.320, V.334, F.335, K.341, E.443, L.445, E.452, V.511, F.585, S.586, W.587, F.588
- Ligands: MTA.31
17 PLIP interactions:17 interactions with chain E- Hydrophobic interactions: E:Q.317, E:L.320, E:L.320, E:V.334, E:F.588
- Hydrogen bonds: E:Q.317, E:K.341, E:L.445, E:E.452, E:S.586, E:S.586, E:F.588
- pi-Stacking: E:F.335, E:F.335, E:W.587, E:W.587, E:W.587
01.47: 15 residues within 4Å:- Chain G: Q.317, S.318, L.320, V.334, F.335, K.341, E.443, L.445, E.452, V.511, F.585, S.586, W.587, F.588
- Ligands: MTA.46
17 PLIP interactions:17 interactions with chain G- Hydrophobic interactions: G:Q.317, G:L.320, G:L.320, G:V.334, G:F.588
- Hydrogen bonds: G:Q.317, G:K.341, G:L.445, G:E.452, G:S.586, G:S.586, G:F.588
- pi-Stacking: G:F.335, G:F.335, G:W.587, G:W.587, G:W.587
- 8 x CL: CHLORIDE ION(Non-functional Binders)
CL.3: 2 residues within 4Å:- Chain A: L.316, Y.510
Ligand excluded by PLIPCL.14: 1 residues within 4Å:- Chain B: G.84
Ligand excluded by PLIPCL.18: 2 residues within 4Å:- Chain C: L.316, Y.510
Ligand excluded by PLIPCL.29: 1 residues within 4Å:- Chain D: G.84
Ligand excluded by PLIPCL.33: 2 residues within 4Å:- Chain E: L.316, Y.510
Ligand excluded by PLIPCL.44: 1 residues within 4Å:- Chain F: G.84
Ligand excluded by PLIPCL.48: 2 residues within 4Å:- Chain G: L.316, Y.510
Ligand excluded by PLIPCL.59: 1 residues within 4Å:- Chain H: G.84
Ligand excluded by PLIP- 40 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.4: 10 residues within 4Å:- Chain A: L.119, G.122, A.123, L.127, A.129, F.130, H.149, S.157, M.158, F.159
Ligand excluded by PLIPEDO.5: 6 residues within 4Å:- Chain A: P.403, N.404, V.407
- Chain G: F.54, Q.74, Q.117
Ligand excluded by PLIPEDO.6: 6 residues within 4Å:- Chain A: K.93, L.94, L.131, L.132, P.133, R.162
Ligand excluded by PLIPEDO.7: 7 residues within 4Å:- Chain A: I.226, W.229, L.230, I.234, R.264, L.265, L.268
Ligand excluded by PLIPEDO.8: 7 residues within 4Å:- Chain A: W.194, D.227, R.228, L.230, S.484, H.518, T.554
Ligand excluded by PLIPEDO.9: 7 residues within 4Å:- Chain A: P.164, L.165, V.166, L.171, E.215, I.216, G.217
Ligand excluded by PLIPEDO.10: 4 residues within 4Å:- Chain A: Y.543, C.544, T.545
- Chain C: R.108
Ligand excluded by PLIPEDO.11: 5 residues within 4Å:- Chain A: F.48, T.88, P.128, W.160, Q.271
Ligand excluded by PLIPEDO.12: 6 residues within 4Å:- Chain A: E.475, Y.476, T.477, E.564, T.565, V.566
Ligand excluded by PLIPEDO.15: 7 residues within 4Å:- Chain B: N.198, R.199, I.200, Q.213, I.214, G.215, C.216
Ligand excluded by PLIPEDO.19: 10 residues within 4Å:- Chain C: L.119, G.122, A.123, L.127, A.129, F.130, H.149, S.157, M.158, F.159
Ligand excluded by PLIPEDO.20: 6 residues within 4Å:- Chain C: P.403, N.404, V.407
- Chain E: F.54, Q.74, Q.117
Ligand excluded by PLIPEDO.21: 6 residues within 4Å:- Chain C: K.93, L.94, L.131, L.132, P.133, R.162
Ligand excluded by PLIPEDO.22: 7 residues within 4Å:- Chain C: I.226, W.229, L.230, I.234, R.264, L.265, L.268
Ligand excluded by PLIPEDO.23: 7 residues within 4Å:- Chain C: W.194, D.227, R.228, L.230, S.484, H.518, T.554
Ligand excluded by PLIPEDO.24: 7 residues within 4Å:- Chain C: P.164, L.165, V.166, L.171, E.215, I.216, G.217
Ligand excluded by PLIPEDO.25: 4 residues within 4Å:- Chain A: R.108
- Chain C: Y.543, C.544, T.545
Ligand excluded by PLIPEDO.26: 5 residues within 4Å:- Chain C: F.48, T.88, P.128, W.160, Q.271
Ligand excluded by PLIPEDO.27: 6 residues within 4Å:- Chain C: E.475, Y.476, T.477, E.564, T.565, V.566
Ligand excluded by PLIPEDO.30: 7 residues within 4Å:- Chain D: N.198, R.199, I.200, Q.213, I.214, G.215, C.216
Ligand excluded by PLIPEDO.34: 10 residues within 4Å:- Chain E: L.119, G.122, A.123, L.127, A.129, F.130, H.149, S.157, M.158, F.159
Ligand excluded by PLIPEDO.35: 6 residues within 4Å:- Chain C: F.54, Q.74, Q.117
- Chain E: P.403, N.404, V.407
Ligand excluded by PLIPEDO.36: 6 residues within 4Å:- Chain E: K.93, L.94, L.131, L.132, P.133, R.162
Ligand excluded by PLIPEDO.37: 7 residues within 4Å:- Chain E: I.226, W.229, L.230, I.234, R.264, L.265, L.268
Ligand excluded by PLIPEDO.38: 7 residues within 4Å:- Chain E: W.194, D.227, R.228, L.230, S.484, H.518, T.554
Ligand excluded by PLIPEDO.39: 7 residues within 4Å:- Chain E: P.164, L.165, V.166, L.171, E.215, I.216, G.217
Ligand excluded by PLIPEDO.40: 4 residues within 4Å:- Chain E: Y.543, C.544, T.545
- Chain G: R.108
Ligand excluded by PLIPEDO.41: 5 residues within 4Å:- Chain E: F.48, T.88, P.128, W.160, Q.271
Ligand excluded by PLIPEDO.42: 6 residues within 4Å:- Chain E: E.475, Y.476, T.477, E.564, T.565, V.566
Ligand excluded by PLIPEDO.45: 7 residues within 4Å:- Chain F: N.198, R.199, I.200, Q.213, I.214, G.215, C.216
Ligand excluded by PLIPEDO.49: 10 residues within 4Å:- Chain G: L.119, G.122, A.123, L.127, A.129, F.130, H.149, S.157, M.158, F.159
Ligand excluded by PLIPEDO.50: 6 residues within 4Å:- Chain A: F.54, Q.74, Q.117
- Chain G: P.403, N.404, V.407
Ligand excluded by PLIPEDO.51: 6 residues within 4Å:- Chain G: K.93, L.94, L.131, L.132, P.133, R.162
Ligand excluded by PLIPEDO.52: 7 residues within 4Å:- Chain G: I.226, W.229, L.230, I.234, R.264, L.265, L.268
Ligand excluded by PLIPEDO.53: 7 residues within 4Å:- Chain G: W.194, D.227, R.228, L.230, S.484, H.518, T.554
Ligand excluded by PLIPEDO.54: 7 residues within 4Å:- Chain G: P.164, L.165, V.166, L.171, E.215, I.216, G.217
Ligand excluded by PLIPEDO.55: 4 residues within 4Å:- Chain E: R.108
- Chain G: Y.543, C.544, T.545
Ligand excluded by PLIPEDO.56: 5 residues within 4Å:- Chain G: F.48, T.88, P.128, W.160, Q.271
Ligand excluded by PLIPEDO.57: 6 residues within 4Å:- Chain G: E.475, Y.476, T.477, E.564, T.565, V.566
Ligand excluded by PLIPEDO.60: 7 residues within 4Å:- Chain H: N.198, R.199, I.200, Q.213, I.214, G.215, C.216
Ligand excluded by PLIP- 4 x GOL: GLYCEROL(Non-functional Binders)
GOL.13: 8 residues within 4Å:- Chain A: E.137, D.138, N.139, T.140, N.199, L.203
- Chain C: R.609, T.626
8 PLIP interactions:2 interactions with chain C, 6 interactions with chain A- Hydrogen bonds: C:R.609, A:E.137, A:E.137, A:N.139, A:T.140, A:N.199
- Water bridges: C:T.626, A:N.139
GOL.28: 8 residues within 4Å:- Chain A: R.609, T.626
- Chain C: E.137, D.138, N.139, T.140, N.199, L.203
8 PLIP interactions:6 interactions with chain C, 2 interactions with chain A- Hydrogen bonds: C:E.137, C:E.137, C:N.139, C:T.140, C:N.199, A:R.609
- Water bridges: C:N.139, A:T.626
GOL.43: 8 residues within 4Å:- Chain E: E.137, D.138, N.139, T.140, N.199, L.203
- Chain G: R.609, T.626
6 PLIP interactions:4 interactions with chain E, 2 interactions with chain G- Hydrogen bonds: E:E.137, E:N.139, E:N.199, G:R.609
- Water bridges: E:N.139, G:T.626
GOL.58: 8 residues within 4Å:- Chain E: R.609, T.626
- Chain G: E.137, D.138, N.139, T.140, N.199, L.203
6 PLIP interactions:4 interactions with chain G, 2 interactions with chain E- Hydrogen bonds: G:E.137, G:N.139, G:N.199, E:R.609
- Water bridges: G:N.139, E:T.626
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cottrell, K.M. et al., Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion. J.Med.Chem. (2025)
- Release Date
- 2025-03-12
- Peptides
- Protein arginine N-methyltransferase 5: ACEG
Methylosome protein 50: BDFH - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
AE
AG
AB
BD
BF
BH
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.37 Å
- Oligo State
- hetero-4-4-mer
- Ligands
- 4 x MTA: 5'-DEOXY-5'-METHYLTHIOADENOSINE(Non-covalent)
- 4 x 01: N-(4-amino-1H-pyrazolo[4,3-c]pyridin-7-yl)-2-[(2R,5S)-2-(1,3-benzothiazol-5-yl)-5-methylpiperidin-1-yl]-2-oxoacetamide
- 8 x CL: CHLORIDE ION(Non-functional Binders)
- 40 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- 4 x GOL: GLYCEROL(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cottrell, K.M. et al., Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion. J.Med.Chem. (2025)
- Release Date
- 2025-03-12
- Peptides
- Protein arginine N-methyltransferase 5: ACEG
Methylosome protein 50: BDFH - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
AE
AG
AB
BD
BF
BH
B